1. Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 
Joseph R. Mikhael, MD, David Dingli, MD, PhD, Vivek Roy, MD, Craig B. Reeder, MD, Francis K. Buadi, MD, Suzanne R. Hayman, MD, Angela Dispenzieri, MD, Rafael Fonseca, MD, Taimur Sher, MD, Robert A. Kyle, MD, Yi Lin, MD, PhD, Stephen J. Russell, MD, PhD, Shaji Kumar, MD, P. Leif Bergsagel, MD, Steven R. Zeldenrust, MD, PhD, Nelson Leung, MD, Matthew T. Drake, MD, PhD, Prashant Kapoor, MD, Stephen M. Ansell, MD, PhD, Thomas E. Witzig, MD, John A. Lust, MD, PhD, Robert J. Dalton, MD, Morie A. Gertz, MD, Keith Stewart, MBChB, S. Vincent Rajkumar, MD, Asher Chanan-Khan, MD, Martha Q. Lacy, MD 
Mayo Clinic Proceedings 
Volume 88, Issue 4, Pages (April 2013)
DOI: /j.mayocp
Copyright © 2013 Mayo Foundation for Medical Education and Research Terms and Conditions

2. Figure 1
Mayo Stratification of Myeloma and Risk-Adapted Therapy treatment algorithm for transplant-eligible patients. CR = complete remission; CyBorD = cyclophosphamide-bortezomib-dexamethasone; Rd = lenalidomide-dexamethasone; VRd = bortezomib-lenalidomidedexamethasone.
Mayo Clinic Proceedings  , DOI: ( /j.mayocp )
Copyright © 2013 Mayo Foundation for Medical Education and Research Terms and Conditions

3. Figure 2
Mayo Stratification of Myeloma and Risk-Adapted Therapy treatment algorithm for transplant-ineligible patients. CyBorD = cyclophosphamide-bortezomib-dexamethasone; MP = melphalan-prednisone; MPT = melphalan-prednisone-thalidomide; Rd = lenalidomide-dexamethasone; VRd = bortezomib-lenalidomide-dexamethasone.
Mayo Clinic Proceedings  , DOI: ( /j.mayocp )
Copyright © 2013 Mayo Foundation for Medical Education and Research Terms and Conditions